Inhibrx Biosciences, Inc.(INBX:US)
Market Cap$1.312B
Key Metrics
Price$89.83
Revenue (TTM)$1.3M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$130.19M
EBITDA (TTM)-$114.82M
Op. Margin (TTM)-9.47K%
Dividend Yield-
Holders Yield-
Cash on hand$161.66M
Total Assets$183.97M
Net Assets-$21.04M
Total Debt$180.9M
Key Metrics
Price$89.83
Revenue (TTM)$1.3M
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$130.19M
EBITDA (TTM)-$114.82M
Op. Margin (TTM)-9.47K%
Dividend Yield-
Holders Yield-
Cash on hand$161.66M
Total Assets$183.97M
Net Assets-$21.04M
Total Debt$180.9M
Financials
| Name | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1.3M | $0 | $100K | $0 | $100K | $0 | $1.47M | $119K | $30K | $0 |
Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| $30.93M | $30.74M | $33.81M | $28.69M | $42.9M | $50.03M | $46.8M | $161M | $49.21M | $23.28M | $45.95M | $41.37M | $39.54M | |
| Research and Development | $25.22M | $25.35M | $28.54M | $22.27M | $36.88M | $33.37M | $38.89M | $67.63M | $40.43M | $20.58M | $38.06M | $34.11M | $34.21M |
| Selling, General, and Administrative | $5.71M | $5.4M | $5.28M | $6.42M | $6.02M | $16.66M | $7.9M | $93.37M | $8.78M | $2.7M | $7.89M | $7.26M | $5.33M |
| Other Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | -$30.93M | -$30.92M | -$33.81M | -$27.39M | -$42.9M | -$49.93M | -$46.8M | -$160.9M | -$49.21M | -$21.82M | -$45.83M | -$41.34M | -$39.54M |
| -$2.51M | -$1.91M | -$1.44M | -$1.26M | -$410K | $2.06M | $2.93M | $2.019B | -$59K | -$158K | -$5.96M | -$5.71M | -$70K | |
| Non-Operating Interest Income | $1.01M | $1.31M | $1.78M | $2.12M | $2.33M | $2M | $2.89M | $2.74M | - | - | $2.32M | $2.41M | - |
| Non-Operating Interest Expense | $3.51M | $3.19M | $3.18M | $3.14M | $2.69M | $0 | $0 | $5.36M | - | - | $8.15M | $7.91M | - |
| Other Income/Expense | -$12K | -$39K | -$46K | -$246K | -$50K | $60K | $41K | $2.022B | -$59K | -$158K | -$135K | -$217K | -$70K |
Income Before Tax | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.858B | -$49.27M | -$5.58M | -$51.79M | -$47.05M | -$39.61M |
Income Tax | $0 | $0 | $0 | $2K | $0 | $0 | $0 | $2K | - | -$4K | $2K | $5K | - |
Net Income | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.858B | -$49.27M | -$7.21M | -$51.79M | -$47.05M | -$39.61M |
Minority Interests | - | - | - | - | - | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income to Common | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.858B | -$49.27M | -$7.21M | -$51.79M | -$47.05M | -$39.61M |
Shares Outstanding (Basic) | 15.59M | 15.53M | 15.48M | 15.47M | 15.47M | 15.47M | 15.47M | 14.62M | 14.24M | - | 14.24M | 14.24M | 14.24M |
Shares Outstanding (Diluted) | 15.59M | 15.53M | 15.48M | 15.47M | 15.47M | 15.47M | 15.47M | 14.81M | 14.24M | - | 14.24M | 14.24M | 14.24M |
EPS (Basic) | -$2.15 | -$2.11 | -$2.28 | -$1.85 | -$2.80 | -$3.09 | -$2.84 | $127.10 | -$3.46 | - | -$3.64 | -$3.30 | -$2.78 |
EPS (Diluted) | -$2.15 | -$2.11 | -$2.28 | -$1.85 | -$2.80 | -$3.09 | -$2.84 | $125.48 | -$3.46 | - | -$3.64 | -$3.30 | -$2.78 |
EBIT | -$29.93M | -$29.65M | -$32.08M | -$25.51M | -$40.62M | -$47.87M | -$43.86M | $1.863B | -$49.21M | -$28.61M | -$43.64M | -$39.14M | -$39.54M |
EBITDA | -$29.4M | -$29.09M | -$31.49M | -$24.85M | -$39.95M | -$47.18M | -$43.1M | -$157.65M | -$48.85M | -$28.32M | -$43.33M | -$38.85M | -$39.25M |